How Lipid-Related Genetic Variation May Shape Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) is a heterogeneous neurological disorder in which inflammatory demyelination, neuroaxonal injury and incomplete tissue repair contribute to progressive disability. Although extensive research has identified numerous genetic and environmental determinants of MS susceptibility, the biological factors governing the rate of disability accumulation remain less clearly defined. Zhang and colleagues addressed this gap by investigating whether common genetic variants associated with lipid metabolism or body mass index (BMI) modify clinical progression in MS. Their study, entitled “Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis,” shifts attention from disease onset to the interaction between inherited metabolic predisposition and longitudinal neurological outcomes. This focus is biologically plausible because previous studies have associated higher total cholesterol, low-density lipoprotein cholesterol and total cholesterol-to-high-density lipoprotein ratio with greater disability, whereas higher high-density lipoprotein cholesterol has generally been linked to more favourable outcomes. The central question was therefore not simply whether lipid concentrations correlate with disability, but whether an individual’s genetic background determines how strongly an adverse lipid profile influences the clinical course of MS.
A Longitudinal Framework for Evaluating Gene–Environment Interactions
The analysis was conducted within the Ausimmune Longitudinal, or AusLong, Study, a prospective cohort established to examine factors influencing the onset and early progression of MS. Of the original participants who experienced a first clinical demyelinating event, 184 individuals had subsequently received an MS diagnosis, undergone genome-wide genotyping and completed disability assessments at baseline and at the five-year review. Disability progression was quantified as the annualised change in Expanded Disability Status Scale score, designated ΔEDSS. Serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides were measured at baseline, while non-HDL cholesterol and the total cholesterol-to-HDL ratio were derived from these values. The investigators systematically reviewed previous genome-wide association studies and selected 162 lipid-related single-nucleotide polymorphisms and 97 BMI-related polymorphisms for evaluation. Associations were tested using linear regression adjusted for age, sex, study site and relapse status at the five-year EDSS assessment. The cohort was predominantly female, had a mean age of approximately 38 years and demonstrated an average annual disability increase of 0.29 EDSS points.
Five Lipid-Related Variants Form a Cumulative Genetic Risk Signal
Five lipid-associated polymorphisms—rs2013208, rs9488822, rs17173637, rs10401969 and rs2277862—were nominally associated with annualised EDSS progression. These variants were located in or near the genes RBM5, FRK, TMEM176A, CILP2 and ERGIC3, respectively. None remained individually significant after stringent correction for testing a large number of variants, an important qualification when interpreting the results. Nevertheless, the investigators observed allele-dose patterns for several variants and retained nominal significance in permutation analyses, providing additional, though not definitive, support for the associations. To evaluate their combined influence, the authors constructed a cumulative genetic risk score from the five polymorphisms. This score displayed a highly significant dose-dependent relationship with disability progression. Participants carrying three or fewer risk alleles progressed at an average rate of 0.21 EDSS points per year, whereas those carrying six or more experienced an additional 0.38 EDSS points of annual progression relative to the lowest-risk group. The genetic-risk model accounted for 16% of the observed variance in ΔEDSS. This aggregate result suggests that multiple common variants of individually modest effect may collectively provide more information about clinical progression than any single locus considered in isolation.
Genetic Risk Changes the Clinical Meaning of a Lipid Profile
The most consequential finding was the interaction between cumulative genetic risk and serum lipid measurements. The genetic score significantly modified the associations of both HDL cholesterol and the total cholesterol-to-HDL ratio with disability progression. Among participants carrying four or fewer risk alleles, differences in HDL or total cholesterol-to-HDL ratio were not associated with substantial differences in annualised EDSS change. In contrast, among individuals carrying more than four risk alleles, lower HDL and a higher total cholesterol-to-HDL ratio were associated with markedly faster progression. These patterns are visualised in Figure 1 on page 4, where the disability trajectories of the higher-risk genetic group diverge as lipid profiles become less favourable. The statistical models reinforce the importance of this interaction: an HDL-based model alone explained approximately 4% of disability variance, but the combined lipid and genetic model explained 26%. Similarly, the explanatory value of the total cholesterol-to-HDL ratio increased from approximately 1% to 27% after inclusion of the genetic score. These results imply that the clinical relevance of dyslipidaemia may be conditional rather than uniform: identical lipid values could carry different prognostic implications depending on an individual’s inherited metabolic architecture.
BMI-Related Genetics Did Not Show the Same Interaction Pattern
The findings for BMI-associated variation were substantially weaker. Of the 97 BMI-related polymorphisms examined, only rs2033529 was nominally associated with annualised disability change. The minor allele was associated with lower progression and showed a non-significant tendency toward lower baseline BMI. However, the variant did not significantly interact with baseline BMI in predicting ΔEDSS, and BMI itself did not change significantly during the five-year observation period. Consequently, the study did not provide evidence for a BMI-based gene–environment interaction comparable to that observed for HDL and the total cholesterol-to-HDL ratio. This contrast is scientifically informative because it indicates that the lipid findings cannot automatically be generalised to all metabolic traits. It also suggests that circulating lipid composition may capture biological processes more directly relevant to early MS progression than BMI, which is an indirect measure that does not distinguish adipose distribution, lean mass, dietary composition or metabolic health. Nevertheless, the absence of a strong BMI signal should not be interpreted as proof that adiposity is irrelevant to MS. The authors’ analysis was limited to the selected common variants, the available cohort size and a five-year period during which BMI remained relatively stable.
Potential Biological and Therapeutic Significance
Several mechanisms could explain why lipid-associated variants influence MS progression. Lipids contribute to cell-membrane structure, myelin composition, immune signalling, oxidative stress and vascular health, all of which may affect neuroinflammation or the capacity for remyelination and neural repair. The identified variants may act through changes in circulating lipoproteins, through pleiotropic effects on other biological pathways, or through interactions with additional MS-associated loci. The authors noted, for example, that rs2013208 lies within an intron of RBM5, a gene associated with RNA regulation, while rs17173637 is situated within TMEM176A, which has been reported to show altered expression in the blood of people with MS. Clinically, the results may help explain why trials of statins in MS have produced inconsistent outcomes. The article proposes that lipid-modifying therapy might be most effective in genetically susceptible subgroups whose neurological progression is particularly sensitive to an adverse lipid profile. This remains a hypothesis rather than a treatment recommendation: the study did not test genotype-guided therapy, establish causality or demonstrate that altering lipid concentrations would necessarily slow disability progression. It does, however, offer a rationale for incorporating genetic stratification into future interventional studies.
Limitations, Replication and the Path Toward Precision Neurology
The study’s longitudinal design is a major strength because lipid measurements preceded the observed disability change, while inherited genetic variation is not altered by subsequent disease progression. The five-year follow-up also provided sufficient time for clinically meaningful changes in EDSS to emerge. However, the sample comprised only 184 participants, and none of the individual lipid-associated variants survived correction for multiple comparisons. The cumulative score was constructed from SNPs selected within the same cohort in which its association was tested, which increases the possibility of overfitting and inflated estimates of explained variance. Furthermore, EDSS is weighted toward ambulatory function and does not fully represent cognition, fatigue, upper-limb performance or other dimensions of MS disability. The authors therefore emphasised the continuing risks of both false-positive and false-negative findings and called for replication in independent cohorts and functional investigation of the implicated loci. The study should consequently be viewed as hypothesis-generating but conceptually important. Its principal contribution is the demonstration that metabolic biomarkers may become more informative when interpreted together with genetic susceptibility. If validated, this framework could support a more precise model of MS prognosis in which lipid monitoring, genetic risk profiling and targeted metabolic interventions are integrated rather than evaluated as isolated determinants of disease progression.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Zhang, Y., Zhou, Y., Van Der Mei, I. A., Simpson, S., Ponsonby, A. L., Lucas, R. M., ... & Ausimmune/AusLong Investigators Group. (2019). Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 90(6), 636-641.
